Discontinued — last reported Q4 '25
W.W. Grainger Interest Paid remained flat by 0.0% to $26.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.5%, from $27.75M to $26.50M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 5.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $87.00M | $91.00M | $109.00M | $111.00M | $106.00M |
| YoY Change | — | +4.6% | +19.8% | +1.8% | -4.5% |